Eyebrow OUTBREAKS OBSERVE NO BORDERS Headline Novavax is uniquely qualified to address the enduring need for innovative vaccines Text Who is Novavax? We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide. Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials. Image Caption Dr. Nita Patel, Kelsey Jacobson, Dr. Rhonda Flores, and Dr. Sonia Maciejewski are on the research team working on the genetic sequencing for vaccine candidate development. Main Content Our Team Our team is composed of experts in drug development who understand science, technology, medicine, and their global context. Our deeply experienced team is unified in the quest to reduce the burden of infectious disease around the globe. Secondary content Meet the leaders who work relentlessly to address urgent global health needs. Management Team Board of Directors Corporate Governance Management Team Novavax Board Committees Audit Committee Charter Compensation Committee Charter Nominating and Corporate Governance Committee Charter Research & Development Committee Charter Code of Business Conduct and Ethics Hotline Policy Corporate Governance Guidelines Eyebrow ADDRESSING GLOBAL HEALTH CHALLENGES TOGETHER Main Content Our Partners and Key Collaborators Partners energize our mission and expand our reach Novavax has several active partnerships across the globe. We seek and encourage meaningful partnerships and collaborations with leading biopharma organizations, research institutions, government agencies, and foundations. Our partners and key collaborators Our partners and key collaborators Image Coalition for Epidemic Preparedness Innovations (CEPI) has committed to provide Novavax up to $388 million in funding for development and manufacturing of Novavax’ NVX-CoV2373 coronavirus vaccine candidate against SARS-CoV-2. Learn About Learn More “The real metrics of success for CEPI are whether it can develop the vaccines we need and whether CEPI can ensure that they’re going to be available to the individuals and populations that need them. CEPI is trying to have vaccines developed and tested faster than any previous effort, anywhere, ever. This is what CEPI was created to do. UPDATE Novavax to receive up to $388 million in funding from CEPI for COVID-19 vaccine development and manufacturing Image The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is the Joint Service’s lead for development, acquisition, fielding, and life-cycle support of chemical, biological, radiological, and nuclear defense equipment and medical countermeasures. Learn About Learn More “Our vision is a resilient Joint Force enabled to fight and win, unencumbered by a chemical, biological, radiological, or nuclear environment and championed by innovative and state-of-the-art solutions. UPDATE Novavax awarded Department of Defense contract for COVID-19 vaccine Image Novavax and Serum Institute of India (SII) announced a commercial license agreement for the use of Novavax’ proprietary Matrix-M™ vaccine adjuvant with SII’s malaria vaccine candidate. Learn About Learn More “This will be an important long-term partnership in advancing an innovative potential malaria vaccine. While we have much work to do, this marks a key step forward. Both in the Indian and international markets, Serum Institute of India aims to provide necessary vaccine coverage with ease of access and at affordable prices. UPDATE Novavax and Serum Institute of India have partnered to develop and commercialize a malaria vaccine candidate Image In 2009, Novavax formed CPL Biologicals Ltd., a joint venture with Cadila Pharmaceuticals Ltd., to develop a number of Novavax’ VLP vaccine candidates and certain Cadila therapeutic vaccine candidates for territories in India. Learn About Learn More “Cadila Pharmaceuticals is one of India’s most advanced and respected pharmaceutical companies. In Novavax, we believe that we have found the best combination of an advanced and proven technology platform for creating next generation vaccines. UPDATE Novavax and Cadila Pharmaceuticals Ltd. formed a joint venture to expand vaccine development capabilities and global manufacturing capacity Main Content Request for proposal (RFP) overview Novavax announces projects that are open for competitive bidding. Novavax is developing NVX-CoV2373, a new vaccine for SARS-CoV-2, in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). To rapidly advance the program and deliver experimental vaccine doses as soon as possible, Novavax is requesting proposals for multiple projects. For a list of open requests for proposal or if you would like instructions on how to participate in an RFP issued by Novavax, download our RFP Information Document. Call-to-action buttons Download the RFP Information Document Secondary content For business development inquiries, contact busdev@novavax.com Main navigation ABOUT US OUR PIPELINE SCIENCE AND TECHNOLOGY RESOURCES CAREERS Utility navigation FOR INVESTORS Corporate Governance Stock Information Events SEC Filings Analyst Coverage Investor Relations Contact Annual Report Investor Presentation NEWS COVID-19 Candidate Updates Press Releases & Statements Novavax in the News Join the Press Release List Press Center Contact Us CONTACT US 21 Firstfield Road Gaithersburg, MD 20878 (240) 268-2000 SOCIAL Footer navigation Privacy Policy Terms and Conditions Pay Transparency Nondiscrimination Provision Purchase Order Terms and Conditions This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings. Accept